KH631 / Chengdu Kanghong Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  KH631 / Chengdu Kanghong Pharma
    Enrollment open, Trial primary completion date, Gene therapy:  Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov) -  Sep 25, 2023   
    P1/2,  N=42, Recruiting, 
    These findings suggest that a single subretinal injection of KH631 has the potential to offer a one-time, low-dose treatment for nAMD patients. Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2023 --> Dec 2026
  • ||||||||||  KH631 / Chengdu Kanghong Pharma
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Gene therapy:  Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) -  Aug 21, 2023   
    P1,  N=25, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2023 --> Dec 2026 Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Sep 2027 | Initiation date: Apr 2023 --> Aug 2023 | Trial primary completion date: May 2026 --> Sep 2026
  • ||||||||||  Subretinal Delivery of an AAV Gene Therapy Product Significantly Inhibited the Neovascularization in a Laser-Induced CNV Rhesus Model (Board No. 1384) -  Apr 21, 2023 - Abstract #ASGCT2023ASGCT_2038;    
    Currently available treatments for neovascular Age-related macular degeneration (wAMD) include Conbercept,Aflibercept, Ranibizumab, Faricimab and Bevacizumab which are antibodies targeting the VEGF axis...The purpose of this study is to develop a therapeutic strategy that have a long-lasting effect with reduced administration frequency, potentially even a single administration.We developed a gene therapy medication (KH631) that encodes anti-VEGF (Conbercept) transgene inside a rAAV8 vector (AAV8-Conbercept)...Laser modeling was conducted 28 days post injection for all the animals in both eyes; Two animals were laser injured and injected immediately with 0.5 mg/eye of Conbercept as positive controls. FL test was performed at week-4 post modeling, images show the representative images of fluorescein fundus angiography (FFA).